VivoSeq
Metabolic & Endocrine

Hyperlipidemia

85

Pipeline Programs↗

6

Active Trials↗

39

Companies Involved↗

Hyperlipidemia is a moderately active landscape with 85 programs across 39 companies. The most active players are Aligos Therapeutics, Verve Therapeutics, Inc., Boryung Pharmaceutical Co., Ltd. 18 therapies are approved with 42 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

19/100

Mech. Concentration

22/100

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aligos Therapeutics

1 program

Phase 1V

Verve Therapeutics, Inc.

1 program

Phase 1Boryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd

1 program

Phase 1R

Response Pharmaceuticals

1 program

Phase 2A

Akros Pharma Inc.

1 program

Phase 2C

Chengdu Diao Jiuhong Pharmaceutical Factory

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical10

Atorvastatin Calcium

Merck & Co.

Praluent

Regeneron

Ezetimibe

Organon and Co

Exenatide

AstraZeneca

Acipimox

Boehringer Ingelheim

Phase 14

Fimasartan

Boryung Pharmaceutical Co., Ltd

ALG-055009

Aligos Therapeutics

Rhus (somagh)

Shiraz University of Medical Sciences

VERVE-201

Verve Therapeutics, Inc.

Phase 211

Berberine

Xijing Hospital of Digestive Diseases

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Statin

Bristol-Myers Squibb

Rosiglitazone

Alnylam Pharmaceuticals

Slx-4090

Response Pharmaceuticals

Phase 342

Telmisartan

Boehringer Ingelheim

Bempedoic Acid

Esperion Therapeutics, Inc.

ATAZANAVIR

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Fenofibrate

Jagotec

Evolocumab

Amgen

Approved18

Tirzepatide

Eli Lilly

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Topiramate

Wim Janssens

Niacin

AbbVie

Pitavastatin

Medicure

Analysis

Modality Breakdown

89%

Small molecule

84 of 94 classified programs — the dominant modality here.

11%ALL OTHERSPeptide66%Monoclonal antibody33%RNA therapy11%

Small molecule leads; the ring shows all 94 classified programs, each share of the total. Modality classified for 98% of 98 pipeline programs.

Analysis

Trial Status

80

clinical trials

Completed57 · 71%
Unknown status11 · 14%
Recruiting5 · 6%
Withdrawn4 · 5%
Available1 · 1%
Terminated1 · 1%
Other1 · 1%

Clinical Trials

Trial Activity

80 trials

Zhibitai Capsules for the Treatment of Primary Hyperlipidemia
Recruiting·CChengdu Diao Jiuhong Pharmaceutical Factory·Phase 2·NCT06822946·192 enrolled
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Recruiting·VVerve Therapeutics, Inc.·Phase 1·NCT06451770·36 enrolled
A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 3·NCT07230730·900 enrolled
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT07100418·200 enrolled
Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance: A Randomized Controlled Clinical Trial
Recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·Preclinical·NCT06684106·128 enrolled
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07216482·975 enrolled
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
Completed·AAkeso·Phase 3·NCT05255094·464 enrolled
to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia
Completed·JJW Pharmaceutical·Phase 4·NCT02056847·313 enrolled
Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia
Completed·ZZhejiang University·Phase 3·NCT01878227·420 enrolled
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
Completed·AAkeso·Phase 3·NCT05260411·246 enrolled
Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
Completed·—·Phase 3·NCT00092560·587 enrolled
Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function
Completed·UUMC Utrecht·Phase 4·NCT00189085·20 enrolled
Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia
Completed·YYuhan Corporation·Phase 3·NCT01914432·210 enrolled
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
Completed·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 3·NCT01442987·230 enrolled
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia
Completed·ZZhejiang University·Phase 3·NCT01811082·240 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)